Mazdutide vs TB-500
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.
- Half-Life
- ~7 days
- 2–3 hours
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 2–2.5 mg
- Frequency
- Once weekly
- Twice weekly
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Enhances muscle tissue regeneration
- Accelerates healing of wounds and injuries
- Reduces inflammation and pain
- Improves flexibility and mobility
- Promotes new blood vessel formation
- Supports hair growth and skin health
- May improve cardiac function after injury
- Systemic healing effect — works at distance from injection site
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Injection site discomfort
- Fatigue (rare)
- Headache (rare)
- Stacks With
- —
- —